Lidocaine intradermal - Anesiva

Drug Profile

Lidocaine intradermal - Anesiva

Alternative Names: ALGRX 3268; D-4115; Lidocaine microcrystals; PowderJect Dermal Lignocaine; PowderJect Lidocaine; Zingo

Latest Information Update: 20 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anesiva
  • Developer Anesiva; Marathon Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaesthesia

Most Recent Events

  • 09 Mar 2017 Lidocaine intradermal receives priority review status for Anaesthesia in China
  • 01 Sep 2015 Efficacy and adverse events data from a phase III trial in Anaesthesia released by Marathon Pharmaceuticals
  • 17 Jun 2015 Tribute Pharmaceuticals Canada acquires Medical Futures
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top